Resources from the same session
LBA30 - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
Presenter: Thibault Mazard
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
554MO - Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in <italic>RAS</italic> wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial
Presenter: Gong Chen
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
555MO - Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)
Presenter: Yu Sunakawa
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA30, 554MO and 555MO
Presenter: Gunnar Folprecht
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Slides
Webcast
LBA31 - Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study
Presenter: Yara Verschoor
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
556MO - A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer
Presenter: Feng Wang
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
LBA32 - Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
Presenter: Kai-Keen Shiu
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
557MO - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Clelia Coutzac
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
558MO - Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)
Presenter: Yoshiaki Nakamura
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
559MO - Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials
Presenter: Davide Ciardiello
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast